Topic: corporate governance
An investor group is calling for a split of the CEO and chairman roles, both currently held by Alex Gorsky, to provide better management oversight.
AZ aims to achieve zero carbon emissions from its own operations by 2025 and to become carbon negative along its entire supply chain by 2030.
Sanofi CEO Paul Hudson hinted at a coming shakeup—from diabetes to cancer and R&D to marketing. And he's planning to unveil those plans December 10.
Novartis needs to trace its ethics woes to their roots and apply its stated values to real-life decisions, experts say. Even then, change takes time.
AbbVie investors are calling for a separation of powers between its board chairman and CEO roles following congressional scrutiny and patent fights over its drug Humira.
A Sun distributor allegedly inked transactions worth $816 million with a firm controlled by Sun’s co-promoter Sudhir Valia.
Though managing director Dilip Shanghvi tried to allay investors' concerns, a couple of key questions remain unanswered.
AstraZeneca slashed CEO Pascal Soriot’s total pay by 34% in 2017, but that cut wasn’t deep enough for one influential voice on corporate governance.
Eli Lilly is moving to a new marketing model to manage expenses, but will ad agencies lose work as Lilly looks to bring more services in-house?
It's official: GlaxoSmithKline CEO Andrew Witty is moving on. At the helm of the U.K.-based drugmaker since 2008, Witty will step down in March 2017, clearing the way for a new captain to chart a new course.